Aurinia Pharmaceuticals Inc (AUPH) : $1.67 million worth of transactions were on upticks in Aurinia Pharmaceuticals Inc (AUPH), compared to $1.33 million on downticks. The ratio between the two was 1.26, whereas, the net money flow stood at a healthy $0.34 million on Mondays session.The block trades show a bullish bias with only $0.06 million worth of transactions done on downticks. The consistent buying on upticks in the stock accounted for $0.19million worth of trades. The up-down ratio between the uptick and downtick was 3.29, confirming that the stronger hands have been buying the stock on every weakness. The total money flow into the stock stood at $0.13 million. The bulls and the bears were in an equilibrium as the stock closed with a loss of -54.28%. The stock was trading at $1.87, with a drop of $2.22 over the previous days close. The stock recorded -48.06% for the week.
Aurinia Pharmaceuticals Inc. has lost 50.68% in the last five trading days and dropped 40.46% in the last 4 weeks. Aurinia Pharmaceuticals Inc. has dropped 20.96% during the last 3-month period . Year-to-Date the stock performance stands at -26.72%.
Aurinia Pharmaceuticals Inc (NASDAQ:AUPH): The stock opened at $2.18 on Monday but the bulls could not build on the opening and the stock topped out at $2.20 for the day. The stock traded down to $1.74 during the day, due to lack of any buying support eventually closed down at $1.81 with a loss of -55.75% for the day. The stock had closed at $4.09 on the previous day. The total traded volume was 11,892,637 shares.
Aurinia Pharmaceuticals Inc. (Aurinia) is a Canada-based is a clinical stage pharmaceutical company. The Company is focused on the development of its therapeutic immunomodulating drug candidate, voclosporin, which is a calcineurin inhibitor (CNI). Voclosporin is an oral drug, administered twice daily. It is structurally similar to cyclosporine A (CsA), but is chemically modified on the amino acid-1 residue. Voclosporin is used as a treatment for lupus nephritis (LN). LN is an inflammation of the kidney that if untreated or inadequately treated can lead to end-stage renal disease, the requirement for life-long dialysis, or death. The Company had completed two Phase III studies of voclosporin in patients with moderate to severe psoriasis. The Company had completed a Phase IIb clinical trial of voclosporin in de novo renal transplant recipients. The Companys wholly owned subsidiaries include Aurinia Pharmaceuticals, Inc. and Aurinia Pharma Limited.